Neurohumoral improvement and torsional dynamics in patients with heart failure after treatment with levosimendan

Romina Navarrì, Stefano Lunghetti, Matteo Cameli, Sergio Mondillo, Roberto Favilla, Francesca Scarpini, Luca Puccetti

A R T I C L E   I N F O

Article history:
Received 30 April 2014
Revised in revised form 5 August 2014
Accepted 26 October 2014
Available online 13 November 2014

Keywords:
Heart failure
Levosimendan
Strain echocardiography
Cytokines

A B S T R A C T

Background: Levosimendan improves clinical and hemodynamic parameters exerting an anti-inflammatory and antiapoptotic effect in decompensated heart failure. The aim of this study was to evaluate the effects of levosimendan on LV torsion, plasma levels of NT-proBNP and on the balance between pro-inflammatory (TNF-α, IL-6) and anti-inflammatory cytokines (IL-10).

Methods: We enrolled 24 patients (age 62 ± 7 years) with acute HF, NYHA class IV and severe LV dysfunction. All patients underwent transthoracic echocardiography using two-dimensional speckle tracking analysis to detect LV twist angle (LVTA), at baseline and 1 week after treatment with levosimendan infusion. Biochemical parameters (pro-BNP, IL-6, IL-10, TNF-α) were determined by enzyme-linked immunosorbent (ELISA).

Results: After one week, we observed an improvement in LV function especially in LVTA (4.15 ± 2.54 vs 2.9 ± 2.1 p < 0.01), in LV ejection fraction (27.3 ± 8.04 vs 21.6 ± 6.8 p = 0.03) and also a significant reduction in BNP levels (1844 ± 560 vs 4713 ± 1050, p = 0.03). The multiple linear regression analysis showed a significant relation between a reduction of TNF-α/IL-10 ratio (Δ > 20%) and BNP (Δ > 40%), LVEF (Δ > 10%) and LVTA (Δ > 20%) (O.R. 1.77, 95% CI. 1.11–2.83; O.R. 1.49, 95% CI. 1.08–2.06; O.R. 1.66, 95% CI. 1.10–2.74, respectively, confirmed p, all < 0.01 by Hosmer–Lemeshow confirmation and the formal test for interaction).

Conclusions: Levosimendan exerts a hemodynamic effect by improving EF and LV torsion in patients with acute HF in association with a positive effect on the balance between pro and anti-inflammatory cytokines.

© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction

Levosimendan is a calcium sensitizing drug that improves cardiac contractility in systole without impairing relaxation in diastole. This drug may also have a vasodilator action which results in improved cardiac output without increasing myocardial oxygen consumption. An active metabolite of this drug (OR1896) maintains the clinical response for up to 9 days from the end of the continuous infusion [2].

The clinical effect of levosimendan, mainly in terms of reduced mortality or prolonged bridging window to non-medical therapies for advanced heart failure (HF), is still under debate but its efficacy in several settings of cardiovascular disease is likely to be proven in various studies [3].

Left ventricular (LV) torsion is a fundamental component of the normal LV systolic contraction that plays an important role to optimize LV ejection fraction (LVEF). It arises from the reciprocal rotation of the LV apex and base during systole, created by the contraction of its oblique spiral fibers. The evaluation of LV twist angle (LVTA) has been possible by speckle tracking echocardiography (STE) analyzing the net difference in mean rotation between the apex (counterclockwise) and the base (clockwise) [4]. STE has recently been proposed and validated as a feasible method for measuring LV rotation and torsion [5].

Levosimendan also seems to have anti-inflammatory and antiapoptotic properties in decompensated heart failure [1]. Pro-inflammatory cytokines like IL-6 and TNF-α depress myocardial contractility, promote cardiomyocyte apoptosis and contribute to cardiac remodeling [6–8].

The activity of inflammatory cytokines is also influenced by anti-inflammatory molecules such us interleukin (IL-10) which can down-regulate the production of several inflammatory mediators from macrophages and other immune cells [9].

The aim of this study was to investigate the role of levosimendan on systolic function especially on myocardial torsional dynamics and on biochemical parameters like brain natriuretic peptide (BNP) levels and on pro/anti-inflammatory cytokine imbalance.

http://dx.doi.org/10.1016/j.ijcha.2014.10.014
2352-9067/© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
2. Methods

2.1. Study population

We enrolled twenty-four consecutive patients (age 62 ± 7 years) with acute NYHA class IV heart failure and severe LV dysfunction (LVEF < 30%). Informed consent was obtained from all subjects and the protocol was approved by the ethics committee of the recruiting center as an extension of previous authorization for similar experimental models [12]. Exclusion criteria were: systolic blood pressure < 80 mm Hg, heart rate > 130 bpm, recent myocardial infarction (<8 weeks) or active myocardial ischemia, serum creatinine levels higher than 2.5 mg/dl (or glomerular filtration rate lower than 30 ml/min) or dialysis, hepatic failure, acute or chronic infectious or inflammatory diseases. All patients were on appropriate medical therapy including beta-blockers, ACE-inhibitors and diuretics and all patients were treated additionally with continuous 24-h infusion of levosimendan at 0.1 μg/kg/min without an intravenous loading dose (see Table 1 for details).

2.2. Standard echocardiography

Echocardiographic studies were performed using a high quality portable echocardiograph (Vivid i GE USA) equipped with a 2.5 MHz transducer. Subjects were studied in the left lateral recumbent position. Echocardiography was performed by experienced physicians at baseline and one week after levosimendan treatment. Measurements of LV end diastolic and end systolic volumes (LV EDV and LV ESV respectively), left atrial dimensions, LVEF and diastolic LV filling were made in accordance with current recommendations of ASE [10]. LVEF, measured using the biplane modified Simpson’s method, was employed as a standard index of global LV systolic function. LV diastolic function was estimated by pulsed wave (PW) Doppler on transmitral flow assessing peak velocities in early (E) and late diastole (A), E/A ratio.

2.3. Tissue Doppler imaging and M-mode annulus excursion analysis

Left ventricular longitudinal function was explored by pulsed tissue Doppler imaging, placing the sample volume at the level of mitral lateral annulus from the apical four chamber view. Peak systolic (Sm), early diastolic (Em), and late diastolic (Am) annular velocities were obtained. The E/Em ratio was also calculated and used as index of LV filling pressures. M-mode measurements of mitral annular plane systolic excursion (MAPSE) were performed by placing the cursor perpendicular to the lateral site of the annulus. Tricuspid annular plane systolic excursion (TAPSE) was also measured using two dimensional guided M-mode imaging [11].

For the assessment of LVTA, LV short-axis planes were obtained at basal and apical levels at adequate frame rates (range 60–90 fps). The basal plane was defined at the level of the mitral valve, whereas the apical plane was acquired distally to the papillary muscles. STE analysis was performed using a dedicated software (Echo Pac, GE USA). After manual delineation of LV endocardial border using a point-and-click approach a second epicardial tracing was automatically generated by the system. The software automatically segmented the LV circumference into six myocardial segments generating rotation curves for each segment. Two mean LV rotation curves representing basal and apical rotation were obtained. LVTA was calculated as the net difference in mean rotation between the apical and basal levels. LV untwisting rate was calculated as the early diastolic peak time derivative of the time-twisting angle curve [12].

2.5. Biochemical measurements

Peripheral venous blood samples were collected by a 19 gage needle without stasis at baseline and one week after treatment with levosimendan infusion to detect cytokine levels (IL-6, IL-10, TNF-α) measured by enzyme-linked immunosorbent assay (ELISA) and plasma BNP levels using the bedside device Triage BNP test (Biosite San Diego, CA) as previously described [12].

2.6. Statistical analysis

Statistical analysis was performed using the SPSS 12.0 statistical package for Windows. Quantitative values were expressed as mean ± standard deviation and qualitative values as %. The Wilcoxon’s paired test was used to compare values before and after drug administration. A two-tailed p value < 0.05 was considered significant.

A multiple logistic regression analysis was employed to evaluate the putative relations among studied variables once corrected for basic (age, BMI, pharmacological treatments and other established diagnosis) and measurable parameters changes evaluated during the study (PAS, PAD, heart rate, LVEF, LVTA). In particular we categorized a 5% growing differences range (both positive or negative trend, 0–4.9, 5–9.9, 10–14.9% and so on) in parameters of cardiac function (LVESV, LVEDV, LVEF, LVTA and BNP) as the primary end-point to relate with TNFα, IL6, IL10 and each to other ratios. Furthermore the statistical model consisting of a formal test for interaction was employed to determine the putative interaction for each single variable. Briefly, starting from logistic regression analysis in which Y was the parametric obtained modification of each single evaluated parameter; the variables X1 and X2 were the present or not (1 or 0) of categorized ranges of cytokine modifications and X3 the combination. The simplified formula for calculation was: $Y = \beta_0 + \beta_1X_1 + \beta_2X_2 + \beta_3X_3$ and the null hypothesis was tested as $H_0: \beta_3 = 0$. Final validation of data was assessed by a resampling technique (Exact Tests in SPSS 2003 module) and discrimination analysis by the Hosmer–Lemeshow method $G^2_{HL} = \sum_{j=1}^{10} (O_j - E_j)^2 / E_j$ ($1 - E_j/n_j - X^2_{E_j}$ where $n_j$ = number of observations in the jth group, $O_j = \sum_{i=1}^{n_j} y_i$ = observed number of positive cases in the jth group, $E_j = \sum_{i=1}^{n_j} y_i$ = expected number of positive cases in the jth group.

3. Results

After one week, clinical, echocardiographic and neurohumoral controls were performed. The general characteristics and echocardiographic parameters of the studied patients are summarized in Tables 1–3 respectively.

Echocardiographic and speckle tracking evaluation after one week from the end of treatment demonstrated a significant improvement of LV systolic function resulting in an increase of LVEF (27.3 ± 8.04 vs...
Table 2
Echocardiographic and speckle tracking data pre- and post-treatment with levosimendan.

| Parameters                        | Baseline (N = 24) | One week (N = 24) | p value |
|----------------------------------|-------------------|-------------------|---------|
| LVEDD (mm)                       | 75.5 ± 11.52      | 75.25 ± 11.14     | p = ns  |
| LVEDS (mm)                       | 65.1 ± 10.7       | 64.62 ± 10.11     | p = ns  |
| LVEDV (ml)                       | 314.12 ± 160      | 280.8 ± 96.95     | p = ns  |
| LVEVS (ml)                       | 226 ± 125         | 216.75 ± 82.10    | p = ns  |
| LVEF (%)                         | 21.6 ± 6.8        | 27.3 ± 8.04       | p = 0.03|
| E (m/s)                          | 0.78 ± 0.2        | 0.77 ± 0.2        | p = ns  |
| A (m/s)                          | 0.3 ± 0.7         | 0.55 ± 0.2        | p = ns  |
| Em (m/s)                         | 0.04 ± 0.01       | 0.05 ± 0.007      | p = ns  |
| Am (m/s)                         | 0.07 ± 0.02       | 0.09 ± 0.04       | p = ns  |
| MAPSE (mm)                       | 9 ± 2             | 11.25 ± 4.02      | p = ns  |
| LV twist angle (°)               | 2.9 ± 2.1         | 4.1 ± 2.5         | p = 0.01|
| LV untwisting                    | −39 ± 36.2        | −35.9 ± 22        | p = ns  |
| LV systolic fraction base (%)    | −5.76 ± 2.4       | −9.58 ± 2.6       | p = ns  |
| LV systolic fraction base (%)    | −4.29 ± 2.2       | −5.35 ± 1.9       | p = ns  |
| PVLS (%)                         | 6.3 ± 3           | 7.3 ± 3.3         | p = ns  |
| PALS (%)                         | 9.3 ± 7.3         | 12 ± 4.7          | p = ns  |

Data are expressed as mean ± standard deviation. Quantitative values were expressed as mean ± standard deviation. The Wilcoxon’s paired test was used to compare values before and after drug administration. A p value < 0.05 was considered significant.

Abbreviations: LVEDD and LVEDS left ventricle end-diastolic and end-systolic diameter respectively, LVEDV left ventricle end diastolic volume, LV systolic fraction base longitudinal strain of left ventricle, and PALS peak longitudinal strain left atrium.

Table 3
Cytokines and BNP values pre- and post-one week from treatment with levosimendan.

| Parameters                        | Baseline | One week | p value |
|----------------------------------|----------|----------|---------|
| IL-6 (pg/ml)                     | 11.6 ± 1.4| 8.3 ± 0.9 | p < 0.05|
| IL-10 (pg/ml)                    | 5.8 ± 0.5 | 8.8 ± 0.7 | p < 0.001|
| TNF-α (pg/ml)                    | 13.1 ± 19 | 8.9 ± 0.8 | p < 0.05 |
| TNF-α/IL-10 ratio                | 2.22 ± 1.6| 1.01 ± 0.6| p < 0.01 |
| BNP (pg/ml)                      | 4713 ± 1050| 1844 ± 560| p = 0.03 |

Data are expressed as mean ± standard deviation. The Wilcoxon’s paired test was used to compare values before and after drug administration. A p value < 0.05 was considered significant.

Abbreviations: BNP brain natriuretic peptide, IL interleukin.

4. Discussion

Levosimendan induced changes in hemodynamic and clinical parameters. Additionally the effect of this treatment in patients with heart failure has been shown to be reflected in change in plasma concentrations of neurohormonal and inflammatory markers [11]. In the present study a cohort of patients with decompensated heart failure was treated with the calcium sensitizer levosimendan and clinical, echocardiographic and laboratory parameters were evaluated to further assess the putative clinical benefit of this drug.

4.1. Echocardiographic and speckle tracking examination

Levosimendan improves echocardiographic indexes of systolic function after seven days from the end of treatment. Our study demonstrated an increase in LVEF and in LV torsional dynamics in patients with acute heart failure and treated with levosimendan. Previous studies have demonstrated that levosimendan improves LV systolic and diastolic function [13]. LV systolic contraction is a complex phenomenon resulting from interaction among different myocardial layers, leading to simultaneous longitudinal and circumferential shortening, radial thickening and twisting [14]. Left ventricular twisting is a component of the normal LV systolic contraction and represents the instantaneous
4.2. Neurohormonal response to levosimendan

In our patient population, levosimendan resulted in a significant reduction of BNP and pro-inflammatory cytokine (TNF-\(\alpha\), IL-6) circulating levels after one week from the end of treatment. This reduction was accompanied by a significant increase of LVEF and LV twisting.

It is well known that overexpression of circulating pro-inflammatory cytokines leads to increased oxidative stress and enhanced cardiomyocyte and endothelial cell apoptosis and plays an important role in the clinical and hemodynamic deterioration of heart failure [15]. At the same time overproduction of BNP in heart failure is a result of elevated end-diastolic cardiac wall stress. High levels of BNP and IL-6 are independent risk factors for morbidity and mortality in patients with heart failure, despite an improvement in LVEF and symptoms after medical therapy [16].

In the present study we demonstrated that levosimendan plays an important role in the imbalance between pro- and anti-inflammatory cytokines: it reduces the levels of IL-6 and TNF-\(\alpha\) and increases the anti-inflammatory IL-10 levels that can downregulate the production of several inflammatory mediators from macrophages and other immune cells [8].

In our study we found an important reduction of TNF-\(\alpha\)/IL-10 ratio that showed a significant correlation with LV twist, so we can confirm that levosimendan has an inotropic and anti-inflammatory role also in the setting of non-ischemic dilated cardiomyopathy (50% of our patients) with respect to post-ischemic dilated cardiomyopathy as previously demonstrated and actually confirmed [12]. The anti-inflammatory effects of levosimendan could be related to an indirect action on circulating cytokines mediated by the improvement of cardiac hemodynamics. However previous evidences have described as a relevant pathogenetic mechanism the imbalance between pro- and anti-inflammatory cytokines involved even before the development of HF in the initial stages of ischemic acute coronary syndromes [17].

Thus, a direct anti-inflammatory effect of levosimendan can be strongly suggested according to the previous demonstration of down-regulation of apoptosis signaling mechanism through inhibition of TNF-\(\alpha\) receptor superfamily and Fas/fas ligand system with subsequent positive effect on cardiomyocytes loss as a consequence of apoptotic cell death [12].

Taking into account that the effects of levosimendan in our study have been ascertained in a population of on top medical treated subjects, including several molecules known to exert an anti-inflammatory effect [18] (see Table 1), the incremental positive effect on cytokine imbalance is more likely due to a direct effect than to an indirect one linked to changes in cardiac hemodynamics.

The positive effect of levosimendan in neurohormonal balance has been suggested also for repeated infusions when a clinical improvement was established in terms of HF progression with a positive trend for 1-year mortality [18]. Furthermore the treatment with levosimendan has been suggested to reach an economically positive profile in acute HF [18].

5. Conclusions

Levosimendan exerts a positive effect on hemodynamic and clinical parameters improving myocardial contractility without increasing myocardial oxygen consumption. In patients with advanced heart failure the increase of LV torsional dynamics appears to be a compensatory mechanism of the failing heart.

Our study demonstrates that levosimendan also induces changes in neurohumoral markers having a beneficial influence in the balance between pro- and anti-inflammatory cytokines and in cardiac remodeling in patients with HF of ischemic or other etiology.

6. Limitations

An important limitation of the clinical use of STE is that to obtain correct endocardial border delineation an adequate echocardiographic view is recommended and furthermore STE is closely dependent from heart rate and it is not possible to conduct strain measurements in patients with non-sinus rhythms. Furthermore, the latter reduces the number of eligible patients in the setting of HF.

Sources of funding

The study was partially supported by a Grant from University of Siena (PAR 2007) to LP

Conflict of interest

The authors report no relationships that could be construed as a conflict of interest.

References

[1] Innes CA, Wagstaff AJ. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 2003;63:2651–71 [Pubmed: 14636085].
[2] Landoni G, Biondi-Zoccai G, Greco M, et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2012;40:534–46 [Pubmed: 21935788].
[3] Mondillo S, Galderisi M, Mele D, et al. Speckle tracking echocardiography: a new technique for assessing myocardial function. J Ultrasound Med 2011;30:71–83 [Pubmed: 21935707].
[4] Helle-Valle T, Crosby J, Edwardsen T, et al. New noninvasive method for assessment of left ventricular rotation: speckle tracking echocardiography. Circulation 2005; 112:3149–56 [PubMed:16286806].

[5] Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83:376–82 [PubMed:10072227].

[6] Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537–44 [PubMed:10716453].

[7] Plenz G, Song ZF, Tjan TD, et al. Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail 2001;3:415–21 [PubMed:11511426].

[8] Mallat Z, Bernard S, Duriez M, et al. Protective role of interleukin 10 in atherosclerosis. Circ Res 1999; 17–24 [PubMed:10521249].

[9] Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440–63 [PubMed:16376782].

[10] Yu CM, Sanderson JE, Marwick TH, et al. Tissue Doppler imaging a new prognosticator for cardiovascular disease. J Am Coll Cardiol 2007;49:1903–14 [PubMed:17488573].

[11] Mondillo S, Galderisi M, Mele D, et al. Speckle tracking echocardiography. J Ultrasound Med 2011;30:71–83 [PubMed:21193707].

[12] Lunghetti S, Palmerini E, Urselli R, et al. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure. Cardiol J 2011;5:532–7 [PubMed:21947989].

[13] Mizuguchi Y, Oishi Y, Miyoshi H, et al. The functional role of longitudinal, circumferential and radial myocardial deformation for regulating the early impairment of left ventricular contraction and relaxation in patients with cardiovascular risk factors: a study with two-dimensional strain imaging. J Am Soc Echocardiogr 2008;21:1138–44 [PubMed:18926389].

[14] Sasayama S, Matsumori A, Kihara Y. New insights into the pathophysiological role for cytokines in heart failure. Cardiovasc Res 1999;42:557–64 [PubMed 10535591].

[15] Adamopoulos S, Parissis JT, Kremastinos DT, et al. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001;3:517–26 [PubMed 11595599].

[16] Pasqui AL, Di Renzo M, Auteri A, et al. Cytokines in acute coronary syndromes. Int J Cardiol 2005;105:355–6 [PubMed 16216352].

[17] Puccetti L, Pasqui AL, Scarpini F, et al. Statins discontinuation in compliant chronic users induces atherothrombotic profile despite baseline clinical settings and treatments. Int J Cardiol 2011;153:328–9 [PubMed 22000266].

[18] Lucioni C, D’Ambrosi A, Mazzi S, Polisello P, Apajasalo M, Fedele F. Economic evaluation of levosimendan versus dobutamine for the treatment of acute heart failure in Italy. Adv Ther Dec 2012;29:1037–50 [PubMed 23233357].